LENZ Therapeutics (LENZ) CEO adds 28,089 shares in open-market stock purchase
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
LENZ Therapeutics director and CEO Evert B. Schimmelpennink made an open-market purchase of 28,089 shares of Common Stock. The shares were bought on March 27, 2026 at a weighted average price of $8.9505 per share, within a price range of $8.80 to $9.25. Following this transaction, he directly owns 77,289 shares of LENZ Therapeutics Common Stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 28,089 shares ($251,411)
Net Buy
1 txn
Insider
Schimmelpennink Evert B.
Role
President, CEO and Secretary
Bought
28,089 shs ($251K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 28,089 | $8.9505 | $251K |
Holdings After Transaction:
Common Stock — 77,289 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did LENZ (LENZ) report for Evert B. Schimmelpennink?
LENZ Therapeutics reported that Evert B. Schimmelpennink executed an open-market purchase of 28,089 shares of Common Stock. This buy transaction increases his direct ownership stake and reflects a personal capital commitment at recently prevailing market prices.
Was the LENZ (LENZ) insider trade a market purchase or another type of transaction?
The insider activity was an open-market purchase of Common Stock, coded as “P” in the Form 4. This indicates shares were bought on the market or in a private transaction, rather than being granted, exercised from options, or transferred as a gift.
What does the weighted average price mean in the LENZ (LENZ) Form 4 filing?
The weighted average price of $8.9505 reflects multiple individual trades totaling 28,089 shares executed between $8.80 and $9.25. The insider notes readiness to provide detailed share counts at each specific price level to the SEC, issuer, or security holders upon request.